10x Genomics, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +2.3%
EBITDA: +183.8%
EBIT: +77.5%
EPS: +86.9%
Free cash flow: +175.4%
Operating cash flow: +125.3%

Forward estimates

Revenue: -1.0%
EBITDA: —
EPS: —

Three-year CAGR

Revenue: +7.6%
EBITDA: +102.9%
EBIT: +43.0%
Net income: +76.2%
EPS: +77.0%
Free cash flow: +2371.2%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.